Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
DAC-002 by Hangzhou DAC Biotech for Small-Cell Lung Cancer: Likelihood of Approval
DAC-002 is under clinical development by Hangzhou DAC Biotech and currently in Phase I for Small-Cell Lung Cancer. According to...
Data Insights
DAC-002 by Hangzhou DAC Biotech for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
DAC-002 is under clinical development by Hangzhou DAC Biotech and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...